

**Cisplatin-induced nephrotoxicity and** electrolyte imbalances in hyperthermic intraperitoneal chemotherapy (HIPEC)



Y. Rial Domínguez<sup>1</sup>, C. Cremades Artacho<sup>1</sup>, I. Carro Méndez<sup>1</sup>, E. Carcelero San Martín<sup>1</sup>, I. Monge-Escartín<sup>1</sup>, G. Riu Viladoms<sup>1</sup>, A. Escolà-Rodríguez<sup>1</sup>, P. Vargas Guerras<sup>1</sup>, A.M. Otero Piñeiro<sup>2</sup>, J. Maurel<sup>3</sup>, D. Soy Muner<sup>1</sup>

<sup>1</sup>Pharmacy Service. Division of Medicines. Hospital Clínic Barcelona, Spain

<sup>2</sup> Peritoneal Oncological Surgery Unit, General Surgery Department. Hospital Clínic Barcelona, Spain <sup>3</sup> Medical Oncological Service. Hospital Clínic Barcelona, Spain



### **Background and Importance**

- HIPEC with cisplatin during cytoreductive surgery offers survival benefits in peritoneal carcinomatosis.
- The prevalence of postoperative acute kidney injury (AKI) can be as high as 48%.

• Prophylactic treatment with sodium thiosulfate (ST) can be effective to avoid this complication, but evidence is weak.

• Cisplatin can also cause electrolyte imbalances, especially hypernatremia and hypokalemia.

## **Aim and Objectives**


- To evaluate renal toxicity of HIPEC with cisplatin while using ST as prophylaxis possible alterations in serum potassium and sodium levels caused by the procedure


## **Materials and Methods**

- Retrospective observational study, which included demographic and clinical data of patients treated with
- HIPEC with cisplatin from January 2023 to June 2024 at a tertiary university hospital.
- All patients received prophylaxis against AKI with ST and adequate hydration. ST was administered as a 10 g bolus 15 minutes before HIPEC and as a 10 g 6-hour perfusion afterwards.
- Renal function was assessed by blood parameters applying Kidney Disease Improving Global Outcomes

# Results

- 38 patients were included (63.2% women), with a median age of 67 (IQR: 52, 72) years old.
- Three patients (7.9%) developed AKI stage I. There were no cases of AKI stage II or III.





- Of those with hypokalemia (33), 69.6% were mild, 26.1% moderate and 4.3% severe.
- Magnesium serum levels were not monitored frequently enough to allow for evaluation.

ST was not associated with any significant

adverse effects.

\*POD: postoperative day

## **Conclusion and Relevance**

• Sodium thiosulfate may be a safe and effective prophylactic treatment for cisplatin-induced AKI in HIPEC.

Further studies are needed to strengthen these findings.

• Electrolyte imbalances are a frequent adverse effect of HIPEC with cisplatin, especially mild hypokalemia.

#### 5PSQ-080 – ATC: L01 – **RIAL@clinic.cat**